Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-7819
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy ; volume:21 ; number:1 ; day:21 ; month:2 ; year:2023 ; pages:1 ; date:12.2023
World journal of surgical oncology ; 21, Heft 1 (21.2.2023), 1, 12.2023
- Creator
-
Oner, Gizem
Önder, Semen
Karatay, Hüseyin
Ak, Naziye
Tükenmez, Mustafa
Müslümanoğlu, Mahmut
İğci, Abdullah
Dincçağ, Ahmet
Özmen, Vahit
Aydiner, Adnan
Yavuz, Ekrem
Cabioğlu, Neslihan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12957-023-02931-z
- URN
-
urn:nbn:de:101:1-2023042721134196872156
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Oner, Gizem
- Önder, Semen
- Karatay, Hüseyin
- Ak, Naziye
- Tükenmez, Mustafa
- Müslümanoğlu, Mahmut
- İğci, Abdullah
- Dincçağ, Ahmet
- Özmen, Vahit
- Aydiner, Adnan
- Yavuz, Ekrem
- Cabioğlu, Neslihan
- SpringerLink (Online service)
Other Objects (12)
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen